Summary
Different doses of phenylbutazone have been compared in a double blind study on 32 patients with rheumatoid arthritis in order to determine the minimum effective dose. Of 8 different dose levels studied (90 mg, 150 mg, 180 mg, 240 mg, 270 mg, 300 mg, 360 mg and 450 mg/day) the most efficacious was found to be 300 mg/day. Doses below this did not produce full benefit; no further improvement occurs with higher doses. Although 7/32 patients developed adverse reactions there was no relationship between these and the plasma levels of either phenylbutazone or oxyphenbutazone. An attempt was made to distinguish ‘responders’ from ‘non-responders’. We found no relationship between response and plasma levels of phenylbutazone or oxyphenbutazone.
Similar content being viewed by others
References
Fjellstrom KE, Goldberg L, Lindren G, Nilsson F (1957) Phenylbutazone in active period of rheumatoid arthritis. Acta Med Scand 320 [Suppl 157]: 1–49
Fowler PD (1967) Marrow toxicity and the pyrazoles. Ann Rheumatol Dis 26: 344–345
Brooks PM, Walker JJ, Dick WC, Anderson JA, Fowler PD (1975) Phenylbutazone: A clinico-pharmalogical study in rheumatoid arthritis. Br J Clin Pharmacol 2: 437–442
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bird, H.A., Leatham, P.A., Lowe, J.R. et al. A phenylbutazone dose-finding study in rheumatoid arthritis. Eur J Clin Pharmacol 24, 773–776 (1983). https://doi.org/10.1007/BF00607086
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00607086